NCT04260191

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

Conditions

• Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	AMG 910	IV Infusion

Timeline

• Start date: 2020-06-29
• Primary completion: 2022-06-02
• Completion: 2022-06-02
• First posted: 2020-02-07
• Last updated: 2024-01-25
• Results posted: 2024-01-25

Locations

20 sites across 9 countries: United States, Austria, France, Germany, Japan, Netherlands, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study